81 tracked 13F filers disclose a position in EVMN as of the latest SEC 13F filings, a combined $547.4M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Position value | Shares | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | EQT Fund Management S.a r.l. | $70.3M | 5.3M | ▲+7.3% Added · +359K sh | Q2 2026 | |
| 2 | RA CAPITAL MANAGEMENT, L.P. | $80.3M | 3.5M | ▲+1.0% Added · +36K sh | Q1 2026 | |
| 3 | RTW INVESTMENTS, LP | $20.0M | 1.5M | —Held | Q2 2026 | |
| 4 | JPMORGAN CHASE & CO | $32.1M | 1.5M | ▲+11% Added · +151K sh | Q1 2026 | |
| 5 | MPM BioImpact LLC | $33.5M | 1.5M | ▲13× Added · +1.3M sh | Q1 2026 | |
| 6 | Andera Partners | $18.5M | 1.4M | ▼−27% Reduced · −505K sh | Q2 2026 | |
| 7 | EVENTIDE ASSET MANAGEMENT, LLC | $27.8M | 1.2M | ▲+26% Added · +248K sh | Q1 2026 | |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | $25.7M | 1.1M | ▲+43% Added · +337K sh | Q1 2026 | |
| 9 | Janus Henderson Group Ltd. | $20.6M | 897K | ▲New +897K sh | Q1 2026 | |
| 10 | MARSHALL WACE, LLP | $20.2M | 880K | ▼−11% Reduced · −108K sh | Q1 2026 | |
| 11 | BAKER BROS. ADVISORS LP | $19.5M | 847K | ▲New +847K sh | Q1 2026 | |
| 12 | Alyeska Investment Group, L.P. | $16.7M | 726K | ▲New +726K sh | Q1 2026 | |
| 13 | Defilade Capital Management, L.P. | $15.6M | 679K | ▲+215% Added · +463K sh | Q1 2026 | |
| 14 | BlackRock, Inc. | $15.5M | 674K | ▲+373% Added · +531K sh | Q1 2026 | |
| 15 | Kynam Capital Management, LP | $14.4M | 625K | ▲+237% Added · +440K sh | Q1 2026 | |
| 16 | AMERICAN CENTURY COMPANIES INC | $11.3M | 493K | ▲+18% Added · +75K sh | Q1 2026 | |
| 17 | VANGUARD CAPITAL MANAGEMENT LLC | $10.5M | 455K | →First observed position No prior filed position | Q1 2026 | |
| 18 | Velan Capital Investment Management LP | $6.0M | 451K | ▲+1.1% Added · +5K sh | Q2 2026 | |
| 19 | PERCEPTIVE ADVISORS LLC | $10.3M | 448K | ▲New +448K sh | Q1 2026 | |
| 20 | Freestone Grove Partners LP | $7.8M | 337K | ▲New +337K sh | Q1 2026 | |
| 21 | FEDERATED HERMES, INC. | $7.5M | 325K | —Held | Q1 2026 | |
| 22 | GREAT POINT PARTNERS LLC | $7.5M | 325K | —Held | Q1 2026 | |
| 23 | GEODE CAPITAL MANAGEMENT, LLC | $4.0M | 302K | ▲+21% Added · +53K sh | Q2 2026 | |
| 24 | UBS Group AG | $6.9M | 298K | ▲87× Added · +295K sh | Q1 2026 | |
| 25 | STATE STREET CORP | $3.9M | 294K | ▲+64% Added · +114K sh | Q2 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 18 funds opened a new position in EVMN and 13 added to an existing one, while 10 reduced and 0 exited entirely — based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Combined value |
|---|---|---|
| CYTOKINETICS INCCYTK | 33 funds | $775.3M |
| ELI LILLY & COLLY | 31 funds | $27.3B |
| COGENT BIOSCIENCES INCCOGT | 31 funds | $979.1M |
| INTUITIVE SURGICAL INCISRG | 30 funds | $10.3B |
| VIRIDIAN THERAPEUTICS INCVRDN | 30 funds | $263.3M |
| AMAZON.COM INCAMZN | 29 funds | $61.0B |
| UNITEDHEALTH GROUP INCUNH | 29 funds | $9.8B |
| INSMED INCINSM | 29 funds | $2.9B |
| REVOLUTION MEDICINES INCRVMD | 29 funds | $2.7B |
| CELCUITY INCCELC | 29 funds | $1.9B |
| EDGEWISE THERAPEUTICS INCEWTX | 29 funds | $1.0B |
| DIANTHUS THERAPEUTICS INCDNTH | 29 funds | $810.4M |
Ranked by how many of EVMN's institutional holders also hold each name, a cross-fund conviction signal.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jul 8, 2026 | Carver Kyle | Chief Financial Officer | Buy (P) | 1K | $13K |
| Jul 7, 2026 | KIRSCH ARTHUR S | Director | Buy (P) | 10K | $133K |
| Jun 22, 2026 | Drew Janice Suzann | Chief of Dev. Operations | Sell (S) | 20K | $453K |
| Jun 22, 2026 | Patel Jeegar Pravinkumar | Chief Scientific Officer | Sell (S) | 1K | $33K |
| Jun 22, 2026 | Pena Luis C. | President & CEO, Director | Sell (S) | 7K | $169K |
| Jun 2, 2026 | Cohen David E | Director | Sell (S) | 5K | $110K |
| Jun 2, 2026 | Cohen David E | Director | Sell (S) | 600 | $13K |
| Jun 1, 2026 | Patel Jeegar Pravinkumar | Chief Scientific Officer | Sell (S) | 17K | $379K |
| Jun 1, 2026 | Pena Luis C. | President & CEO, Director | Sell (S) | 17K | $382K |
| May 28, 2026 | Moss Gregory S. | Chief Business & Legal Officer | Sell (S) | 14K | $325K |
| May 28, 2026 | Carver Kyle | Chief Financial Officer | Sell (S) | 18K | $415K |
| Dec 19, 2025 | Hopfner Robert Lorne | Director, 10% Owner | Buy (P) | 1K | $17K |
Connected entities for EVMN
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/EVMN/capital-change-brief"
Use Arkolith's capital_change_brief for EVMN. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for EVMN. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.